Mendelian randomization study with clinical follow-up links metabolites to risk and severity of pulmonary arterial hypertension
Author(s)
Type
Journal Article
Abstract
BACKGROUND: Pulmonary arterial hypertension (PAH) exhibits phenotypic heterogeneity and variable response to therapy. The metabolome has been implicated in the pathogenesis of PAH, but previous works have lacked power to implicate specific metabolites. Mendelian randomization (MR) is a method for causal inference between exposures and outcomes. METHODS AND RESULTS: Using genome-wide association study summary statistics, we implemented MR analysis to test for potential causal relationships between serum concentration of 575 metabolites and PAH. Five metabolites were causally associated with the risk of PAH after multiple testing correction. Next, we measured serum concentration of candidate metabolites in an independent clinical cohort of 449 patients with PAH to check whether metabolite concentrations are correlated with markers of disease severity. Of the 5 candidates nominated by our MR work, serine was negatively associated and homostachydrine was positively associated with clinical severity of PAH via direct measurement in this independent clinical cohort. Finally we used conditional and orthogonal approaches to explore the biology underlying our lead metabolites. Rare variant burden testing was carried out using whole exome sequencing data from 578 PAH cases and 361 675 controls. Multivariable MR is an extension of MR that uses a single set of instrumental single-nucleotide polymorphisms to measure multiple exposures; multivariable MR is used to determine interdependence between the effects of different exposures on a single outcome. Rare variant analysis demonstrated that loss-of-function mutations within activating transcription factor 4, a transcription factor responsible for upregulation of serine synthesis under conditions of serine starvation, are associated with higher risk for PAH. Homostachydrine is a xenobiotic metabolite that is structurally related to l-proline betaine, which has previously been linked to modulation of inflammation and tissue remodeling in PAH. Our multivariable MR analysis suggests that the effect of l-proline betaine is actually mediated indirectly via homostachydrine. CONCLUSIONS: Our data present a method for study of the metabolome in the context of PAH, and suggests several candidates for further evaluation and translational research.
Date Issued
2024-03-19
Date Acceptance
2023-10-18
Citation
Journal of the American Heart Association, 2024, 13 (6)
ISSN
2047-9980
Publisher
Wiley
Journal / Book Title
Journal of the American Heart Association
Volume
13
Issue
6
Copyright Statement
© 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/38456412
Subjects
Familial Primary Pulmonary Hypertension
Follow-Up Studies
Genome-Wide Association Study
Humans
Mendelian Randomization Analysis
Pulmonary Arterial Hypertension
Serine
homostachydrine
Mendelian randomization
metabolome
pulmonary arterial hypertension
serine
Publication Status
Published
Coverage Spatial
England
Article Number
e032256
Date Publish Online
2024-03-08